Author

Xi Zhang

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Efficacy and safety of induction benmelstobart plus anlotinib and chemotherapy followed by concurrent chemoradiotherapy and benmelstobart consolidation versus concurrent chemoradiotherapy followed by benmelstobart consolidation in patients with unresectable stage III NSCLC: a randomized, controlled,

Background The PACIFIC and GEMSTONE-301 trials established consolidation immunotherapy post-chemoradiotherapy for unresectable stage III NSCLC, but 22–30% of patients fail initial chemoradiotherapy, precluding consolidation. PACIFIC-2 and CheckMate 73L failures highlight the need for better integration. Induction chemo...

Ze-Wen Song, Shu-Yun Ma, Xi Zhang et al. · Frontiers in Immunology · 0 citations

Review Open access Oct 2026

Benmelstobart With or Without Anlotinib After Chemoradiotherapy for Unresectable Non-Small Cell Lung Cancer: The R-ALPS Randomized Clinical Trial.

This randomized clinical trial found that benmelstobart with or without anlotinib significantly improved progression-free survival (PFS) compared with placebo and adding anlotinib did not significantly improve PFS compared with benmelstobart alone and increased severe and fatal treatment-related adverse events.

Yong-Ling Ji, Qi-Wen Li, Long Chen et al. · JAMA Oncology · 0 citations